|
A Study of Ribavirin in the Treatment of Patients with AIDS and AIDS-Related Problems Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about A Study of Ribavirin in the Treatment of Patients with AIDS and AIDS-Related Problems conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. A Study of Ribavirin in the Treatment of Patients with AIDS and AIDS-Related Problems Clinical research trials and A Study of Ribavirin in the Treatment of Patients with AIDS and AIDS-Related Problems medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like A Study of Ribavirin in the Treatment of Patients with AIDS and AIDS-Related Problems. A Study of Ribavirin in the Treatment of Patients with AIDS and AIDS-Related Problems Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a A Study of Ribavirin in the Treatment of Patients with AIDS and AIDS-Related Problems clinical trial. Test subjects typically obtain the finest healthcare available for their A Study of Ribavirin in the Treatment of Patients with AIDS and AIDS-Related Problems condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Study of Ribavirin in the Treatment of Patients with AIDS and AIDS-Related Problems  A Study of Ribavirin in the Treatment of Patients with AIDS and AIDS-Related Problems
A Study of Ribavirin in the Treatment of Patients with AIDS and AIDS-Related Problems
For Condition: HIV Infections
Status: Completed
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: To determine the maximum long-term dosage of ribavirin (RBV) that is safe and free of serious side effects in patients with AIDS or AIDS related illnesses. Also, to determine what effect different dosage levels have on biologic markers of efficacy, such as the amount of the AIDS virus (HIV) or number of T cells in the patient's blood. RBV is a new drug capable of inhibiting the growth of the AIDS virus in the laboratory with little effect on normal human cells. In earlier tests of RBV in AIDS patients, the drug was well tolerated and safe, and this favorable result suggested that RBV should be more extensively studied in patients with AIDS and advanced AIDS related complex (ARC).
Details: RBV is a new drug capable of inhibiting the growth of the AIDS virus in the laboratory with little effect on normal human cells. In earlier tests of RBV in AIDS patients, the drug was well tolerated and safe, and this favorable result suggested that RBV should be more extensively studied in patients with AIDS and advanced AIDS related complex (ARC). Patients are selected from three patient groups: o Patients with AIDS, who have not taken zidovudine (AZT) within 30 days of entry into the study and who have not been discontinued from AZT because of intolerance. o Patients with AIDS related diseases who have not taken AZT within 30 days of entry into the study, and who have not been discontinued from AZT because of intolerance. o Patients with AIDS or AIDS related diseases who have had AZT intolerance that required cessation of therapy. This is an outpatient study; patients are seen weekly for the first 4 weeks, every other week through week 12, and then every 4 weeks for the duration of the 24 weeks of the treatment portion of the study. Patients from each of the three diagnostic groups are enrolled at each dose level. For the first 3 days after entry into the study, all patients receive the lowest dose of RBV every 6 hours. Subsequent dosages increase until the maximum tolerated dose (MTD) is reached. The MTD for a group is defined as the dose at which 4 or more of the 8 patients in the group develop toxicity which requires a change or discontinuation of the dosage. Patients who experience significant toxicity may continue in the study at lower dose to determine the long-term tolerance.
Eligibility:
Study Type: Interventional, Treatment, Open Label, Pharmacokinetics Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria Concurrent Medication: Allowed: - Short-course therapy (7 days) with oral acyclovir. - Short-course therapy (7 days) with ketoconazole. - Topical medications. - Aerosolized pentamidine for prophylactic purposes. Concurrent Treatment: Allowed: - Blood transfusions for hemoglobin toxicity. Patients must have two positive HIV p24 antigen tests with titers = or > 70 picograms at least 72 hours apart and within 1 month prior to entry, the last of which must be within 2 weeks of starting therapy. Prior Medication: Allowed: - Zidovudine (AZT), without cessation of therapy required due to intolerance. - AZT therapy must be discontinued at least 30 days prior to study entry. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - Active opportunistic infection, symptomatic visceral Kaposi's sarcoma (KS) or progression of KS within the month prior to entry into the study, neoplasms other than KS, basal cell carcinoma of the skin, or in situ carcinoma of the cervix. Significant diarrhea, defined as = or > 3 liquid stools per day within the past week. Concurrent Medication: Excluded: - Ongoing systemic therapy and/or prophylaxis for an AIDS-defining opportunistic infection. - Antineoplastic therapy. - Other experimental medications. - Systemic chemoprophylaxis for Pneumocystis carinii pneumonia. - Chronic (> 7 days) oral acyclovir therapy. Concurrent Treatment: Excluded: - Blood transfusions unless they are for = or > grade 3 hemoglobin toxicity. Patients with the following are excluded: - Active opportunistic infection, symptomatic visceral Kaposi's sarcoma (KS) or progression of KS within the month prior to entry into the study, neoplasms other than KS, basal cell carcinoma of the skin, or in situ carcinoma of the cervix. Significant diarrhea, defined as = or > 3 liquid stools per day within the past week. Prior Medication: Excluded within 30 days of study entry: - Antiretroviral agents including zidovudine (AZT). - Biologic modifiers. - Systemic corticosteroids. Prior Treatment: Excluded within 2 months of study entry: - Blood transfusion except for those who have taken zidovudine (AZT) who may not have received a transfusion within the previous month. Active drug or alcohol abuse.
Total Enrollment: 96
Location and Contact Information:
Overall Study Official:
CrumpackerC, Study Chair,
Harvard (Massachusetts Gen Hosp)
Boston, Massachusetts, 02114
United States
Univ of California / San Diego Treatment Ctr
San Diego, California, 921036325
United States
Bellevue Hosp / New York Univ Med Ctr
New York City, New York, 10016
United States
Univ of North Carolina
Chapel Hill, North Carolina, 275997215
United States
San Francisco AIDS Clinic / San Francisco Gen Hosp
San Francisco, California, 941102859
United States
Additional Information:
Study ID Numbers: ACTG 034;
Study Start Date:
Record last reviewed: October 1991
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001015
Other Hiv Infections Studies:
1. A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients
2. Comparison of Stavudine Used Alone or in Combination with Didanosine in HIV-Infected Children
3. The Safety and Effectiveness of Ribavirin in the Early Stages of HIV-Infection
4. Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals
5. Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
Related Studies:
Other HIV Infections Clinical Trials
Other California Clinical Trials
Other San Diego Clinical Trials
A Study of Ribavirin in the Treatment of Patients with AIDS and AIDS-Related Problems
|
|
|
|
|
|
|
|
